Safety, tolerability and pharmacokinetics of sugammadex using single high doses (Up to 96mg/kg) in healthy adult subjects: A randomized, double-blind, crossover, placebo-controlled, single-centre study

Clinical Drug Investigation

Volumn 30, Issue 12, 2010, Pages 867-874

  Peeters, Pierre A M ^a   Van Den Heuvel, Michiel W ^a   Van Heumen, Emiel ^a   Passier, Paul C C M ^a   Smeets, Jean M W ^a   Van Iersel, Thijs ^b   Zwiers, Alex ^a  

^a MSD   (Netherlands)

^b Xendo   (Netherlands)

Author keywords

anaesthesia; neuromuscular blockade; pharmacokinetics.; research and development; sugammadex

Indexed keywords

PLACEBO; SUGAMMADEX;

ABDOMINAL PAIN; ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; DYSGEUSIA; ELECTROCARDIOGRAPHY; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; MALE; NAUSEA; POSITIONAL DIZZINESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SORE THROAT; URINARY URGENCY; VITAL SIGN;

ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GAMMA-CYCLODEXTRINS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NETHERLANDS; NEUROMUSCULAR AGENTS; PLACEBO EFFECT; TREATMENT OUTCOME;

EID: 77957839121     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11538920-000000000-00000     Document Type: Article

References (21)

1. Murphy GS. Residual neuromuscular blockade: incidence, assessment, and relevance in the postoperative period. Minerva Anestesiol 2006 Mar; 72 (3): 97-109
2. EMA. European Public Assessment Report (EPAR). Bridion. EPAR summary for the public, updated June 2010 [online]. Available from URL: http://www.ema. europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000885/ WC500052310.pdf[Accessed 2010 Jul 19]
3. Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 2002 Jan; 41 (2): 266-70
4. Epemolu O, Bom A, Hope F, et al. Reversal ofneuromuscular blockade and simultaneous increase in plasma ro-curonium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology 2003 Sept; 99 (3): 632-7
5. de Boer HD, van Egmond J, van de Pol F, et al. Reversal of profound rocuronium neuromuscular blockade by su-gammadex in anesthetized rhesus monkeys. Anesthesiol-ogy 2006 Apr; 104 (4): 718-23
6. Gijsenbergh F, Ramael S, Houwing N, et al. First human exposure of Org 25969, a novel agent to reverse the action ofrocuronium bromide. Anesthesiology 2005 Oct; 103 (4): 695-703
7. Shields M, Giovanelli M, Mirakhur RK, et al. Org 25969 (sugammadex), a selective relaxant binding agent for ant-agonism ofprolonged rocuronium-induced neuromuscular block. Br J Anaesth 2006 Jan; 96 (1): 36-43
8. Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology 2006 Apr; 104 (4): 667-74
9. Suy K, Morias K, Cammu G, et al. Sugammadex, a selective relaxant binding agent, offers effective reversal ofmoderate rocuronium-or vecuronium-induced neuromuscular block. Anesthesiology 2007 Feb; 106 (6): 283-8
10. de Boer HD, Driessen JJ, Marcus MA, et al. Reversal of rocuronium-induced (1.2mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology 2007 Aug; 107 (2): 239-44
11. Groudine SB, Soto R, Lien C, et al. A randomized, dosefinding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg 2007 Mar; 104 (3): 555-62
12. Sacan O, White PF, Tufanogullari B, et al. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edro-phonium-atropine. AnesthAnalg 2007 Mar; 104 (3): 569-74
13. SparrH J, Vermeyen KM, Beaufort AM, et al. Earlyreversal ofprofound rocuronium-induced neuromuscular block by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology 2007 May; 106 (5): 935-43
14. Vanacker BF, Vermeyen KM, Struys MMRF, et al. Reversal of rocuronium-induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane. An-esth Analg 2007 Mar; 104 (3): 563-8
15. Cammu G, De Kam PJ, Demeyer I, et al. Safety and tolerability of single intravenous doses of sugammadex ad-ministered simultaneously with rocuronium or vecuronium in healthy volunteers. Br J Anaesth 2008 Mar; 100 (3): 373-9
16. Molina AL, de Boer HD, Klimek M, et al. Reversal of rocuronium-induced (1.2mg/kg) profound neuromuscular block by accidental high dose of sugammadex (40mg/kg). Br J Anaesth 2007 May; 98 (5): 624-7
17. de Kam PJ, van Kuijk J, Prohn M, et al. Effects of sugammadex doses up to 32mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study. Clin Drug Investig 2010; 30 (9): 599-611
18. de Kam P-J, van Kuijk J, Smeets J, et al. Single IV sugammadex doses up to 32mg/kg are not associated with QT/QTc prolongation (abstract). Anesthesiology 2007; 107: A1580
19. Organon USA. FDA Anesthetic and Life Support Advisory Committee Meeting: briefing document (background package) for sugammadex sodium injection [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/08/slides/2008-4346s1- 01-Schering-Plough-corebackup. pdf [Accessed 2009 June 30]
20. Stella VJ, He Q. Cyclodextrins. Toxicol Pathol 2008; 36 (1): 30-42
21. Peeters P, Passier P, Smeets J, et al. Sugammadex is cleared rapidly and predominantly in an unchanged form via renal excretion (abstract). Clin Pharmacol Ther 2009; 85: S83